Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average of $1.72

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.72 and traded as high as $1.85. Cumberland Pharmaceuticals shares last traded at $1.63, with a volume of 15,234 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals in a research note on Thursday. They issued a “hold” rating on the stock.

Cumberland Pharmaceuticals Stock Up 4.4 %

The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.53. The firm has a market cap of $23.81 million, a PE ratio of -10.76 and a beta of 0.22. The firm’s 50-day moving average price is $1.93 and its two-hundred day moving average price is $1.72.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of institutional investors have recently made changes to their positions in CPIX. Renaissance Technologies LLC raised its holdings in Cumberland Pharmaceuticals by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after acquiring an additional 38,100 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Cumberland Pharmaceuticals by 27.8% during the 1st quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after acquiring an additional 40,949 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in Cumberland Pharmaceuticals during the second quarter worth approximately $133,000. Bank of New York Mellon Corp purchased a new position in Cumberland Pharmaceuticals during the third quarter worth approximately $142,000. Finally, Millennium Management LLC acquired a new position in shares of Cumberland Pharmaceuticals in the 4th quarter valued at $46,000. 16.70% of the stock is owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.